Profiling of Three H3F3A-mutated and Denosumab-treated Giant Cell Tumors of Bone Points to Diverging Pathways During Progression and Malignant Transformation

Overview

Journal Sci Rep

Specialty Science

Date 2021 Mar 12

PMID 33707617

Citations 11

Authors

Marc Hasenfratz

Kevin Mellert

Ralf Marienfeld

Alexandra von Baer

Markus Schultheiss

P D Roitman

L A Aponte-Tinao

Burkhard Lehner

Peter Moller

Gunhild Mechtersheimer

Thomas F E Barth

Affiliations

Soon will be listed here.

Abstract

Giant cell tumor of bone (GCTB) is a locally aggressive lesion of intermediate malignancy. Malignant transformation of GCTB is a rare event. In 2013, the humanized monoclonal antibody against receptor activator of nuclear factor-κb-Ligand (RANKL) denosumab was approved for treatment of advanced GCTB. Since then, several reports have questioned the role of denosumab during occasional malignant transformation of GCTB. We report on three patients with H3F3A-mutated GCTBs, treated with denosumab. The tissue samples were analysed by histomorphology, immunohistochemistry, and in two instances by next generation panel sequencing of samples before and after treatment. One patient had a mutation of ARID2 in the recurrence of the GCTB under treatment with denosumab. One patient developed a pleomorphic sarcoma and one an osteoblastic osteosarcoma during treatment. Sequencing revealed a persisting H3F3A mutation in the osteosarcoma while the pleomorphic sarcoma lost the H3F3A mutation; however, a FGFR1 mutation, both in the recurrence and in the pleomorphic sarcoma persisted. In addition, the pleomorphic sarcoma showed an AKT2 and a NRAS mutation. These data are inconclusive concerning the role denosumab plays in the event of malignant progression/transformation of GCTB and point to diverging pathways of tumor progression of GCTB associated with this treatment.

Citing Articles

Establishment and characterization of NCC-GCTB10-C1: a novel cell line derived from a patient with recurrent giant cell tumor of bone.

Adachi Y, Noguchi R, Osaki J, Ono T, Akiyama T, Kondo H Hum Cell. 2024; 38(1):29.

PMID: 39653987 DOI: 10.1007/s13577-024-01153-z.

Current indications for denosumab in benign bone tumours.

Imre A, Zoltan S, Miklos S EFORT Open Rev. 2023; 8(12):895-905.

PMID: 38038377 PMC: 10714381. DOI: 10.1530/EOR-23-0138.

Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment.

Arndt S, Hartmann W, Rokusz A, Leinauer B, von Baer A, Schultheiss M Cancers (Basel). 2023; 15(17).

PMID: 37686526 PMC: 10486357. DOI: 10.3390/cancers15174249.

Potential alternative drug treatment for bone giant cell tumor.

Chen Z, Zhang C, Hong H, Xu W, Sha M, Ding Z Front Cell Dev Biol. 2023; 11:1193217.

PMID: 37384251 PMC: 10294225. DOI: 10.3389/fcell.2023.1193217.

Genetic characterization of a novel organoid from human malignant giant-cell tumor.

Suzuki R, Wakamatsu T, Yoshida K, Matsuoka Y, Takami H, Nakai S J Bone Oncol. 2023; 41:100486.

PMID: 37260767 PMC: 10227374. DOI: 10.1016/j.jbo.2023.100486.

References

Liu Y, Zhu S, Wang X, Deng J, Li W, Zhang P . MiR-200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AKT2. Sci Rep. 2017; 7(1):13598. PMC: 5648776. DOI: 10.1038/s41598-017-14088-3. View

Raskin K, Schwab J, Mankin H, Springfield D, Hornicek F . Giant cell tumor of bone. J Am Acad Orthop Surg. 2013; 21(2):118-26. DOI: 10.5435/JAAOS-21-02-118. View

Park A, Cipriano C, Hill K, Kyriakos M, McDonald D . Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report. JBJS Case Connect. 2017; 6(3):e78. DOI: 10.2106/JBJS.CC.16.00024. View

Ellis G, Bone H, Chlebowski R, Paul D, Spadafora S, Smith J . Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008; 26(30):4875-82. DOI: 10.1200/JCO.2008.16.3832. View

Thomas D . RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol. 2012; 24(4):397-403. DOI: 10.1097/CCO.0b013e328354c129. View

Berger A, Schwerdel D, Ettrich T, Hann A, Schmidt S, Kleger A . Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Oncotarget. 2018; 9(2):2076-2085. PMC: 5788622. DOI: 10.18632/oncotarget.23330. View

Alberghini M, Kliskey K, Krenacs T, Picci P, Kindblom L, Forsyth R . Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch. 2009; 456(1):97-103. DOI: 10.1007/s00428-009-0863-2. View

Rutkowski P, Ferrari S, Grimer R, Stalley P, Dijkstra S, Pienkowski A . Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015; 22(9):2860-8. PMC: 4531146. DOI: 10.1245/s10434-015-4634-9. View

Broehm C, Garbrecht E, Wood J, Bocklage T . Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab. Case Rep Med. 2016; 2015:767198. PMC: 4700156. DOI: 10.1155/2015/767198. View

10.

Chawla S, Henshaw R, Seeger L, Choy E, Blay J, Ferrari S . Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013; 14(9):901-8. DOI: 10.1016/S1470-2045(13)70277-8. View

11.

Aponte-Tinao L, Piuzzi N, Roitman P, Farfalli G . A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab. Clin Orthop Relat Res. 2015; 473(9):3050-5. PMC: 4523533. DOI: 10.1007/s11999-015-4249-2. View

12.

Usman Tariq M, Umer M, Khan Z, Saeed J, Siddiqui M, Ud Din N . Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists. Ann Diagn Pathol. 2020; 45:151479. DOI: 10.1016/j.anndiagpath.2020.151479. View

13.

Dahlin D . Caldwell Lecture. Giant cell tumor of bone: highlights of 407 cases. AJR Am J Roentgenol. 1985; 144(5):955-60. DOI: 10.2214/ajr.144.5.955. View

14.

Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S . Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. Cancer Treat Rev. 2014; 41(2):61-8. DOI: 10.1016/j.ctrv.2014.12.001. View

15.

Skubitz K . Giant cell tumor of bone: current treatment options. Curr Treat Options Oncol. 2014; 15(3):507-18. DOI: 10.1007/s11864-014-0289-1. View

16.

JAFFE H . Giant-cell tumour (osteoclastoma) of bone: its pathologic delimitation and the inherent clinical implications. Ann R Coll Surg Engl. 1953; 13(6):343-55. PMC: 2377698. View

17.

Palmerini E, Picci P, Reichardt P, Downey G . Malignancy in Giant Cell Tumor of Bone: A Review of the Literature. Technol Cancer Res Treat. 2019; 18:1533033819840000. PMC: 6446439. DOI: 10.1177/1533033819840000. View

18.

Bertoni F, Bacchini P, Staals E . Malignancy in giant cell tumor of bone. Cancer. 2003; 97(10):2520-9. DOI: 10.1002/cncr.11359. View

19.

Lim Y, Ovejero D, Sugarman J, DeKlotz C, Maruri A, Eichenfield L . Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet. 2013; 23(2):397-407. PMC: 3869357. DOI: 10.1093/hmg/ddt429. View

20.

Campanacci M, Baldini N, Boriani S, Sudanese A . Giant-cell tumor of bone. J Bone Joint Surg Am. 1987; 69(1):106-14. View